Narrative review · PMID 41490200
Injectable Peptide Therapy in Regenerative Medicine and Sports Performance — VialBase Research
Reviews BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu
Last updated · 2026 · Multiple authors (Keck School of Medicine of USC) · American Journal of Sports Medicine
Key findings
- Reviews BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu
- CJC-1295 + ipamorelin improved maximum tetanic tension in murine glucocorticoid-induced muscle loss
- Tesamorelin has no supporting orthopaedic evidence despite FDA approval for lipodystrophy
- GHK-Cu showed promise in wound healing but no clinical musculoskeletal data
- Sermorelin mentioned alongside GHRH peptide class
PMID 41490200 — Injectable Peptide Therapy in Regenerative Medicine
Compound: Sermorelin Citation: Am J Sports Med. 2026. doi:multiple
Summary
Comprehensive literature review evaluating injectable peptide therapy for regenerative medicine and sports performance. Focused on the most popular peptides being marketed to orthopedic patients.
Key Findings
- BPC-157 demonstrates tendon/muscle repair potential but largely unvalidated in human trials
- TB-4 and TB-500 promote angiogenesis and tissue repair preclinically; both remain WADA-banned
- CJC-1295 + ipamorelin showed improved muscle function in glucocorticoid-treated mice
- Tesamorelin has FDA approval for lipodystrophy but zero orthopedic evidence
- GHK-Cu showed wound healing promise but no musculoskeletal clinical data
- Significant methodological flaws in the limited human data available
Relevance to Sermorelin
Sermorelin is grouped with GHRH peptides that have mechanistic rationale for tissue repair via IGF-1 signaling but lack direct orthopedic clinical evidence.
See Also
- Parent compound: Sermorelin
- CJC-1295
- Ipamorelin
- Tesamorelin
- BPC-157
- TB-500
- GHK-Cu